SCHEMBL6006539

SCHEMBL6006539

CCCCCN([C]=O)NC(=O)OCC

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX1 P07099 2/20 0.36
NPSR1 Q6W5P4 1/20 0.35
ACHE P22303 3/20 0.34
KDM5A P29375 6/20 0.34
KDM4C Q9H3R0 3/20 0.33
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
L3MBTL1 Q9Y468 2/20 0.33
MAPT P10636 1/20 0.33
ATM Q13315 1/20 0.33
MAPK1 P28482 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
KDM5C P41229 1/20 0.33
KDM5B Q9UGL1 1/20 0.33
GAA P10253 2/20 0.33
PHF8 Q9UPP1 3/20 0.33
DNM1 Q05193 1/20 0.33
MGAM O43451 1/20 0.32
SI P14410 1/20 0.32
MGAM2 Q2M2H8 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6006518 0.87 EPHX1 (0.49) EPHX1ACHEMAPTMAPK1SMN1; SMN2
SCHEMBL7682621 0.82 KDM5A (0.37) KDM5AKDM4CMEN1KMT2AKDM5C
SCHEMBL6008437 0.81 EPHX1 (0.40) EPHX1ACHE
SCHEMBL6850051 0.80 CA12 (0.41) EPHX1MEN1KMT2A
SCHEMBL7689399 0.77 KDM5A (0.33) EPHX1KDM5AKDM4CMEN1KMT2A
SCHEMBL11837227 0.73 ALOX15 (0.36) EPHX1NPSR1ACHEKDM5AKDM4C
SCHEMBL6005054 0.73 EPHX1 (0.34) EPHX1MAPT
SCHEMBL4282891 0.72 CA12 (0.36) DNM1
SCHEMBL11517386 0.69 DNM1 (0.38) EPHX1KDM5AKDM4CMEN1KMT2A
SCHEMBL11517198 0.69 DNM1 (0.38) EPHX1KDM5AKDM4CMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1207161-B1 NOVEL ISOINDOLE DERIVATIVES BANYU PHARMA CO LTD (JP) 2006-01-18 EP disclosed
US-6777410-B2 SUCH AS 9-(2-METHOXYPHENYL)-3-(1-METHYLETHYL)-(1,3)OXAZOLO-(2,3)ISOINDOLE-2,5(3H,9H)-DIONE; DIABETES AND COMPLICATIONS; OBESITY BANYU PHARMACEUTICAL CO., LTD. (JP) 2004-08-17 US disclosed
US-20040053923-A1 Novel isoindole derivatives BANYU PHARMACEUTICAL CO., LTD. 2004-03-18 US disclosed
US-6608098-B1 Diabetes or obesity, 2-(4-(3-isopropyl-2,5-dioxo-2,3-dihydro-1H-pyrrolo(2,1-a) isoindol-9(5H)-yl)phenoxy)-N-propylacetamide BANYU PHARMACEUTICAL CO., LTD. (JP) 2003-08-19 US disclosed
EP-1207161-A1 NOVEL ISOINDOLE DERIVATIVES BANYU PHARMACEUTICAL CO., LTD. (JP) 2002-05-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040053923-A1 Novel isoindole derivatives GPR119, SLC5A2, SLC5A1 EPHX1 3176/4885NPSR1 758/4885ACHE 4155/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.